Marijuana compound may offer treatment for Alzheimer’s disease

University of South Florida preclinical study indicates

September 1, 2014 - Tampa, FL -- Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer’s disease, a recent study from neuroscientists at the University of South Florida shows. More...

Computerized Cognition Test Provides Better Assessment than Observation

August 28, 2014 - Research published in the Journal of Alzheimer’s Disease this week suggests healthy older adults are less capable of observing their own cognitive decline over an 18 month period than Cogstate’s computerized brief battery (CBB). The study, conducted by neuropsychologists, also indicated that close family members were unable to perceive decline in the cognitive behavior of their partner and trial participant in social settings. More...

Conflicts with Teachers Are Risk Factor for School Shootings

Berlin Group within TARGET Project at Freie Universität Berlin Presents Findings / Evaluated 126 Attacks Worldwide

August 27, 2014 - As part of the TARGET project funded by the German Federal Ministry of Education and Research, researchers at Freie Universität Berlin conducted a systematic literature search of all the available studies dealing with school shootings. The aim of the analysis was to clarify which social dynamics in the social network of perpetrators can be observed in advance as playing an important role in school shootings. Up to now, researchers had assumed that bullying between peers and the social exclusion of the perpetrators were the most prominent factors in school shootings. This study shows, however, that in many cases conflicts with teachers seemed to be a decisive factor in the school shooting cases investigated. More...

Human Brain Deficits of PKCe: Targeted for Alzheimer’s Disease Therapeutic and Diagnostic Trials

August 20, 2014 - Today, researchers at the Blanchette Rockefeller Neurosciences Institute (BRNI) announced findings from a new study entitled, “PKCe Deficits in Alzheimer’s Disease Brains and Skin Fibroblasts.” These new findings offer significant promise for a new therapeutic and diagnostic approach to Alzheimer's disease (AD) that has remained so refractory to effective and early drug treatment. This approach is now the major focus of ongoing clinical trials being conducted by at BRNI/Neurotrope, Inc. collaboration. In contrast to past strategies, this new therapeutic strategy now being clinically tested, not only removes the precursors to amyloid plaques and tangles, it also induces the growth of new synapses and prevents neuronal death. More...